Notice of Intent to Sole Source – Biomerieux
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH - CC
Contract Value
Not provided
Codes & Classification
Solicitation Number
26-004263
NAICS
339112 - Surgical and Medical Instrument Manufacturing
Classification Code
6515
Additional Details
The National Institutes of Health (NIH), through its Clinical Center Office of Purchasing and Contracts, has issued a Special Notice indicating its intent to award a sole source, firm fixed price purchase order to BioMerieux Inc. for the provision of reagents and supplies required for mycoplasma testing and routine laboratory work. This procurement is essential to support the NIH’s current Good Manufacturing Practice (cGMP) program and to ensure the ongoing care of NIH Clinical Center patients.
The scope of this acquisition encompasses a one-year supply of BioMerieux reagents and supplies, which are specifically validated for use with the NIH’s existing laboratory instrumentation and clinical testing protocols. These products have undergone rigorous laboratory validation and are uniquely capable of meeting the stringent regulatory cGMP standards for product sterility testing and environmental monitoring within the Department of Laboratory Medicine (DLM). As such, only BioMerieux’s reagents and supplies are deemed suitable to maintain compliance with these critical regulatory requirements.
The procurement is classified under Product Service Code 6515 (Medical Instruments, Equipment, and Supplies) and North American Industry Classification System (NAICS) code 339112 (Surgical and Medical Instrument Manufacturing), version year 2022. The place of performance for this contract is Bethesda, Maryland (MD 20892), United States.
This action is being conducted in accordance with Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, specifically Subpart 13.106-1(b)(1), which allows for solicitation from a single source when only one source is reasonably available and the acquisition does not exceed the simplified acquisition threshold. As such, this procurement is exempt from the competition requirements outlined in FAR Part 6. No set-aside applies to this notice.
The NIH has determined that BioMerieux is the only source capable of providing the required reagents and supplies due to their compatibility with existing validated systems and their ability to meet regulatory standards. No solicitation document will be issued, and quotations are not being requested. However, interested parties may express their interest and demonstrate their capabilities in response to this notice. The government reserves the right to determine, at its sole discretion, whether to compete the requirement based on responses received.
Comments or expressions of interest referencing this posting number should be directed to Kristin Nagashima, Contract Specialist, via email at [email protected], no later than April 21, 2026, at 12:00 pm EST.
This notice remains active and can be referenced on SAM.gov under Opportunity ID b0bd2ae511024894b85ce45d9b122206. For further details, interested parties may visit the official notice URL: https://sam.gov/opp/b0bd2ae511024894b85ce45d9b122206/view.
In summary, this procurement is a sole source acquisition for specialized laboratory reagents and supplies from BioMerieux, critical to the NIH’s compliance with cGMP standards and the continued support of clinical and research activities at the NIH Clinical Center.